Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Thalassemia
Data on thalassemia described by K. Paciaroni et al
July 20th, 2009
"An adult patient affected by beta(o)-thalassemia major underwent allogeneic bone marrow transplant (BMT) from a matched related donor. Forty days after transplant, allogeneic engraftment failure and autologous beta(o)-thalassemic bone marrow recovery were documented," investigators in Rome, Italy report. "Red blood cell transfusions were required until 118 days post-transplant. Thereafter, the haemoglobin (Hb) levels stabilized over 11.8 gr/dl throughout the ongoing 34-month follow-up, abolishing the need for transfusion support. The Hb electrophoresis showed 100% Hb Fetal (HbF)," wrote K. Paciaroni and colleagues. The researchers concluded: "This...
Source: Biotech Business Week (2009-07-20)
|
